Ayala Pharmaceuticals Inc (OTCMKTS:ADXS) Stock Gains Momentum: Here Is Why

March 6, 2023

Clinical stage oncology firm Ayala Pharmaceuticals Inc (OTCMKTS:ADXS) was one of the companies to have come into the news cycle this past Friday following a key announcement. The company announced that the Independent Data Monitoring Committee (IDMC) concerning the Phase 2/3 of the RINGSIDE study into its product AL102 had completed a prespecificed review of the data and recommended that the study could continue without any changes. Trading Data On…


Advaxis Inc (OTCMKTS:ADXS) Stock On Radar After Q3 Earnings

September 13, 2022

Clinical stage biotech company Advaxis Inc (OTCMKTS:ADXS) could be one of the companies that could be in focus among investors today after it announced its financial results for the third quarter that ended on July 31, 2022 yesterday. Trading Data On Monday, ADXS stock increased 0.33% to $3.0600 with 1.06K shares, compared to its average volume 4.26K shares. The stock moved within a range of $3.0600 – 3.4700 after opening…


Advaxis Inc (OTCMKTS:ADXS) Announces 1-for-80 Reverse Stock Split: Stock Falls

June 6, 2022

Clinical stage biotech firm Advaxis Inc (OTCMKTS:ADXS) had a fairly tough time in the markets this past Friday as its stock went into a downward spiral and ended up with a decline of as much as 18% for the day. Trading Data On Friday, ADXS stock fell 14% to $0.0620 with more than 1.30 million shares, compared to its average volume of 483K shares. The stock moved within a range…


Advaxis Inc (OTCMKTS:ADXS) To take part at the ASCO Annual Meeting

April 28, 2022

Despite making a major announcement on Wednesday, the Advaxis Inc (OTCMKTS:ADXS) stock was in a downward spiral and ended the day with a decline of as much as 7%. In this situation, it may be a good idea for investors to take a look at the announcement from the biotech company and then figure out if the stock is going to recover or not. Trading Data On Wednesday, ADXS stock…